Do not miss this opportunity and submit your application by 23 March 2022
The most influential oncology platform to share your research
From 2022 ASCO Genitourinary Cancers Symposium
Longer follow-up of the phase III study shows a consistent disease-free survival benefit with the postsurgical use of pembrolizumab in patients with renal cell carcinoma and high-risk features
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.